Uganda launches HPV vaccination programme to fight its commonest cancer

BMJ ◽  
2012 ◽  
Vol 345 (sep10 1) ◽  
pp. e6055-e6055 ◽  
Author(s):  
A. Gulland
2018 ◽  
Vol 94 (4) ◽  
pp. 248-253 ◽  
Author(s):  
Stephen Jean ◽  
Malak Elshafei ◽  
Alison Buttenheim

ObjectiveTo assess social patterns in human papillomavirus (HPV) vaccine coverage in a school-based, government-funded vaccination programme located within a single-payer universal healthcare system.DesignWe conducted a cross-sectional analysis of HPV vaccine uptake data for the 2013–2014 school year for 131 local authorities in England, and then evaluated the association between vaccine uptake and socioeconomic status at the aggregate level.Data sourcesHPV vaccination coverage data from Public Health England’s vaccine uptake guidance and the UK’s March 2011 Census.Main outcome measuresWe measured three-dose local authority-level vaccine series initiation to completion.ResultsWe found that in local authorities where there are more high-income families, the vaccination rate is lower than in local authorities with more low-income families. Local authorities with a higher percentage of whites, compared with non-whites, had higher HPV vaccination rates. Additionally, local authorities with more non-migrants had higher rates of vaccination. Local authorities with more education deprivation had higher rates of vaccination. Local authorities’ higher proportions of high-status occupations had worse vaccination coverage. In bivariate analyses across all the socioeconomic indicators, a 1 SD change in the indicators was associated with about a 2.25 percentage point decrease (for income, education and occupation) or increase (for race and migrant composition) in HPV dose coverage in the local authority. In multivariable analyses, only race remained as a significant predictor of HPV coverage at the local authority level.ConclusionsAcross all three doses, there are notable variations by socioeconomic status, with steep reverse gradients in three socioeconomic indicators. More quantitative and qualitative research needs to be conducted to determine the effects of the 2014 transition from a three-dose regimen to two-dose regimen on vaccination coverage, especially in groups that experience lower rates of vaccination.


The Lancet ◽  
2013 ◽  
Vol 382 (9894) ◽  
pp. 768 ◽  
Author(s):  
Stuart Gilmour ◽  
Mikiko Kanda ◽  
Eiji Kusumi ◽  
Tetsuya Tanimoto ◽  
Masahiro Kami ◽  
...  

2014 ◽  
Vol 91 (3) ◽  
pp. 214-219 ◽  
Author(s):  
Eric P F Chow ◽  
Tim R H Read ◽  
Rebecca Wigan ◽  
Basil Donovan ◽  
Marcus Y Chen ◽  
...  

2013 ◽  
Vol 89 (Suppl 1) ◽  
pp. A64.1-A64
Author(s):  
S M Garland ◽  
S O Osborne ◽  
E J Young ◽  
J M L Brotherton ◽  
S N Tabrizi ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. e039029
Author(s):  
Harriet Fisher ◽  
Suzanne Audrey ◽  
Tracey Chantler ◽  
Adam Finn ◽  
Louise Letley ◽  
...  

AimTo co-produce with young people an educational package about the human papillomavirus (HPV) vaccine that is tailored to increase vaccine uptake in schools and populations with lower uptake.IntroductionPersistent infection with HPV can result in cancers affecting men and especially women. From September 2019, the English-schools-based HPV vaccination programme was expanded to include young men (in addition to young women) aged 12–13 years. Some young people attending schools with lower uptake of the vaccine have unmet information needs. We hypothesise that mechanisms to address information needs and increase young people’s autonomy in consent procedures will result in higher uptake.Methods and analysisThe Medical Research Council’s framework for development and evaluation of complex interventions will inform intervention development. Recruitment of young people aged 12–15 years and key stakeholders (National Health Service commissioners, school staff, immunisation nurses and youth workers/practitioners) will be facilitated through existing links with healthcare organisations, schools and youth organisations in areas with lower uptake of the HPV vaccination programme. The proposed research will comprise three phases: (1) a rapid review of adolescent immunisation materials and preliminary qualitative interviews with young people and key stakeholders, (2) theory development and co-production of HPV vaccine communication materials through an iterative process with young people and (iii) testing delivery mechanisms and acceptability of the educational package in four schools with lower uptake.Ethics and disseminationThe University of Bristol’s Faculty of Health Sciences and London School of Hygiene and Tropical Medicine's Research Ethics Committees provided approvals for the study. A dissemination event for young people and key stakeholders and webinar with the National Immunisation Network will be organised. The study findings will be published in peer-reviewed journals and presented at conferences. Recommendations for a future larger scale study will be made.


Sign in / Sign up

Export Citation Format

Share Document